Skip to main content

Table 3 Independent predictors for progression-free and overall survival

From: Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization

Variables

Progression-free survival

Overall survival

 

Univariate

Multivariate

Univariate

Multivariate

 

P value

P value

HR

95% CI

P value

P value

HR

95% CI

Age, years

0.770

 

-

-

0.578

 

-

-

Male

0.028

0.443

-

-

0.013

0.039

2.119

1.040-4.320

Etiology

        

Viral vs. others

0.252

 

-

-

0.916

 

-

-

Anti-viral therapy

0.325

 

-

-

0.047

0.453

-

-

HBV-DNA positivity

0.165

 

-

-

0.231

 

-

-

HBeAg positivity

0.234

 

-

-

0.324

 

-

-

Child-Pugh class, A vs. B

0.040

0.832

-

-

0.787

 

-

-

Liver cirrhosis

0.101

 

-

-

0.002

0.005

2.319

1.281-4.201

GGT

0.001

0.012

1.003

1.001-1.004

0.014

0.068

-

-

Tumor marker

        

Baseline AFP

0.008

0.049

1.000

1.000-1.001

0.486

 

-

-

Baseline DCP

0.039

0.686

-

-

0.001

0.028

1.000

1.000-1.001

AFP response

0.155

 

-

-

0.023

<0.001

0.276

0.147-0.518

DCP response

0.756

 

-

-

0.205

 

-

-

BCLC stage, A vs. ≥B

0.002

0.409

-

-

0.003

0.502

-

-

Number of tumora

0.001

0.373

-

-

<0.001

0.030

1.443

1.035-2.011

Size of Tumorb

0.021

0.927

-

-

<0.001

0.085

-

-

WHO response

        

CR + PR + SD vs. PD

0.419

 

-

-

0.945

 

-

-

mRECIST

        

CR + PR + SD vs. PD

0.107

 

-

-

0.548

 

-

-

  1. anumber of measurable lesion, btotal size of measurable lesion.
  2. HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer.
  3. Reference value: others, Child-Pugh class B, BCLC stage ≥ B, PD with WHO criteria, and PD with mRECIST criteria.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us